Skylands Capital LLC Has $2.53 Million Position in Cytosorbents Co. (NASDAQ:CTSO)

Skylands Capital LLC lifted its stake in Cytosorbents Co. (NASDAQ:CTSO) by 1.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,781,622 shares of the medical research company’s stock after purchasing an additional 26,195 shares during the period. Skylands Capital LLC owned 5.09% of Cytosorbents worth $2,531,000 at the end of the most recent quarter.

Separately, Geode Capital Management LLC increased its holdings in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CTSO has been the subject of a number of research reports. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a report on Monday, January 13th. StockNews.com started coverage on shares of Cytosorbents in a report on Saturday. They set a “hold” rating for the company. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Cytosorbents has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Price Performance

CTSO opened at $1.15 on Monday. The company has a fifty day moving average price of $1.01 and a two-hundred day moving average price of $1.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents Co. has a 52 week low of $0.70 and a 52 week high of $1.61. The firm has a market capitalization of $62.88 million, a PE ratio of -3.19 and a beta of 0.61.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.